Plasma PFDN2 suppresses head and neck squamous cell carcinoma progression by restricting CD64 on monocyte-driven inflammatory microenvironments - PubMed
3 hours ago
- #HNSC
- #CD64
- #PFDN2
- Plasma PFDN2 suppresses head and neck squamous cell carcinoma (HNSC) progression by restricting CD64 on monocytes.
- HNSC is a highly heterogeneous malignancy with poor prognosis and frequent recurrence.
- Multi-sample Mendelian randomization identified PFDN2 as a protective factor against hypopharyngeal carcinoma.
- CD64 on monocytes (FCGR1A+ monocytes) is causally linked to both PFDN2 and cancer risk.
- PFDN2 expression negatively correlates with monocyte infiltration in HNSC.
- Single-cell RNA sequencing shows PFDN2 is predominantly expressed in epithelial tumor cells, while FCGR1A is restricted to monocytes.
- Virtual knockout of PFDN2 activates monocyte-associated inflammatory programs.
- Molecular docking and dynamics simulations support stable PFDN2-CD64 interaction.
- PFDN2 downregulation and CD64 upregulation in HNSC correlate with advanced tumor grade and stage.
- The PFDN2-CD64 axis is a potential prognostic biomarker and therapeutic target.